Disease-associated hepatocytes are predictive of outcomes and survival in MASLD beyond fibrosis staging
Gut
.
2025 Sep 10:gutjnl-2025-336627.
doi: 10.1136/gutjnl-2025-336627.
Online ahead of print.
Authors
Rodrigo Carlessi
#
1
2
,
Timothy James Kendall
#
3
4
,
John K Olynyk
2
5
,
Benjamin J Dwyer
1
2
,
Michael C Wallace
6
7
,
Jonathan A Fallowfield
#
3
,
Janina Ee Tirnitz-Parker
#
8
2
Affiliations
1
Curtin Medical School, Curtin University, Bentley, Western Australia, Australia.
2
Curtin Medical Research Institute, Curtin University, Bentley, Western Australia, Australia.
3
Institute for Regeneration and Repair, University of Edinburgh, Edinburgh, UK.
4
Edinburgh Pathology, University of Edinburgh, Edinburgh, UK.
5
Department of Gastroenterology & Hepatology, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.
6
Department of Hepatology and Western Australian Liver Transplant Service, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
7
Medical School, The University of Western Australia, Perth, Western Australia, Australia.
8
Curtin Medical School, Curtin University, Bentley, Western Australia, Australia N.Tirnitz-Parker@curtin.edu.au.
#
Contributed equally.
PMID:
40930580
DOI:
10.1136/gutjnl-2025-336627
No abstract available
Keywords:
BIOMARKERS; CIRRHOSIS; FATTY LIVER; HEPATOCELLULAR CARCINOMA; HEPATOCYTE.
Publication types
Letter